Uncategorized

Barclays Upgrades Johnson Controls Intl to Overweight, Raises Price Target to $75

Barclays analyst Julian Mitchell upgrades Johnson Controls Intl (NYSE:JCI) from Equal-Weight to Overweight and raises the price target from $67 to $75.

byBenzinga Newsdesk

May 26, 2021

1 minute read

Barclays analyst Julian Mitchell upgrades Johnson Controls Intl (NYSE:JCI) from Equal-Weight to Overweight and raises the price target from $67 to $75.

FDA
News

Avidity Biosciences Announces FDA Grants Fast Track Designation To AOC 1001 For The Treatment Of Myotonic Dystrophy Type 1

By Benzinga Newsdesk

Today, 4:37 AM

Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and

RNA

Peering Into Citigroup Inc’s Recent Short Interest

By Benzinga Insights

Today, 4:37 AM

Citigroup Inc's (NYSE:C) short percent of float has fallen 6.63% since its last report. The company recently reported that it has 36.32 million shares sold short, which is 1.83% of all regular shares that are available for trading.

AstraZeneca’s ALXN1840 Shows Promising Action Against Copper Metabolism Disorder

By Vandana Singh

Today, 4:37 AM

AstraZeneca Plc (NASDAQ:AZN) announced detailed results from the positive FoCus Phase 3 trial of ALXN1840 in Wilson’s disease, an inherited condition…

AZN

Gevo Shares Tick Higher Following Recent Axios Article ‘U.S. unveils roadmap for net-zero aviation emissions by 2050’; BZ NOTE: Gevo Describes Itself as ‘a renewable chemicals and biofuels company…’

By Benzinga Newsdesk

Today, 4:37 AM

https://www.axios.com/transportation-net-zero-aviation-emissions-cop26-288b11c2-3289-4b65-b3f0-321cbb2b0138.html

GEVO

Barclays Upgrades Johnson Controls Intl to Overweight, Raises Price Target to $75

Related Posts

Avidity Biosciences Announces FDA Grants Fast Track Designation To AOC 1001 For The Treatment Of Myotonic Dystrophy Type 1

Peering Into Citigroup Inc’s Recent Short Interest

AstraZeneca’s ALXN1840 Shows Promising Action Against Copper Metabolism Disorder

Gevo Shares Tick Higher Following Recent Axios Article ‘U.S. unveils roadmap for net-zero aviation emissions by 2050’; BZ NOTE: Gevo Describes Itself as ‘a renewable chemicals and biofuels company…’